Medications

Question 1

Ipilimumab

Answer 1

CTLA-4 inhibitor (activated T cell driven immune response)
Indication: unresectable or metatastic malignant melanoma
SE: fatigue, Diarrhea, Pruritus, rash, colitis,

Question 2

Cisplatin

Answer 2

alkylating agent, IV, SE: emetogenic, BM suppression, ototoxic (irreversible), neurotoxic (peripheral neuropathy = reversible) nephrotoxic

Question 3

Doxorubicin

Answer 3

Antracycline. intercalating agents (works in nucleus) insert molecules between DNA or RNA an stop translation. IV. Indications: intravesically for bladder cancer, leukemia. SE: cardiotoxicity: eary: not dose dependent. no indication to stop therapy. Late: Dose dependent. Red discoloration of urine

Question 4

Capecytabine

Answer 4

Is a prodrug of 5-FU, given orally. Indications: Breast, colorectal, pancreatic.
SE: BM supp, GI: NVD, stomatitis. HAND FOOT SYNDROME REACTION

Question 5

tamoxifen

Answer 5

hormonal treatment. In ER pos breast cancer pts. Acts in nucles, taken ORALLY. SE: thrombotic disease, altered lipid profile (decrease in lipids), increased risk of secondary endomterial malignancy, reduce bone resorption.

Question 6

Imatinib

Answer 6

tyrosin kinase inhibitor
Indication; CML (brc-abl kinase), GI; given orally, cytotoxic. Generally well toreated, SE: edema, BM suppression, NV, skin rash

Question 7

Bevacizumab

Answer 7

anti VEGF (anti ligand): indication: colorectal, ovarian. IV. SE: proteinuria/nephrotic syndrome, PE, HTN, bleeding, for would heeling, BM suppression

Question 8

vemurafenib

Answer 8

inhibits BRAF
treatment of malignant melanoma
SE: seconary skin malignanies

Question 9

Transtuzimab

Answer 9

Target HER 2, breast and gastric cancer. IV. SE: CHF, cardiotoxicity

Question 10

Cetuximab

Answer 10

Block EGFR receptor, cimeric –> increased incidence of infuison reactin.
Indications: CRC, H and N, NSCLC
IV
SE: ACNE LIKE SKIN RASH, nail and hair alterations, Hypomg
NB if pts hav k-ras mutation, do not give cetuximab.

Question 11

Nivolumab

Answer 11

metatatic malanoma

SE: nephritis, hypothyroidism, autoimmune reaction.

Question 12

Transuzumab
cetuximab
imatinib
Bevacizumab

Answer 12

HER2
EGFR
brc-abl: CML
VEGF

Question 13

clinical trial

Answer 13

phase 1: safety and dose
phase 2: dose it work
phase 3: new drug vs standardized drug
phase 4: reporting long term SE and advserse SE

Question 14

CTCAE grade of severity of SE

Answer 14

Grade of severity of SE
1: asymp/mild. no intervention
2. moderate
3. severe 
4. lifetheretning
5. death. 
4+ 5 = stop treatment

Question 15

cardiotoxicty

Answer 15

trastuzimab

antracyclines

Question 16

pulmonary fibrosis

Answer 16

bleomycin

Question 17

hemorrhagic cystitis

Answer 17

cyclophsphamid

Question 18

zubrod scale:

Answer 18

0= no signs of disease 
1 = symp but normal activity
2 = symp,  50 %
4 = bed bound 
5 = dying patient 
3-5 = can not receive chemo